scholarly journals The cost of cancer – A comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0241354
Author(s):  
Max Schlueter ◽  
Katie Chan ◽  
Romain Lasry ◽  
Martin Price
Keyword(s):  
Chronic Diseases ◽  
Disease Burden ◽  
Healthcare Expenditure ◽  
Burden Of Illness ◽  
Annual Growth Rate ◽  
Compound Annual Growth Rate ◽  
Disability Adjusted Life ◽  
Payer Perspective ◽  
Care Payer ◽  
The Cost

Background Cancer poses a significant mortality, morbidity, economic and humanistic burden to patients and health systems. This study aims to better understand healthcare expenditure on cancer relative to other major chronic diseases across France, Germany, Italy, Spain and the United Kingdom, whilst also considering the burden of illness posed by these conditions. Methods A targeted literature review was performed to identify and extract relevant demographic, epidemiological and economic data. A health care payer perspective was adopted for the analysis, with a focus on direct healthcare costs. Results Between 2006–2015, the cancer-related disability-adjusted life year (DALY) disease burden decreased by 9.3% despite a 6.5% increase in prevalence. Whilst the per patient drug costs increased by a compound annual growth rate (CAGR) of 5.1%, the overall per patient cancer costs decreased over the 10-year study period (CAGR of -1.4%). Compared to cardiovascular disease, neurological/mental disorders and diabetes, cancer was associated with the highest disease burden (20.8% of DALYs across all diseases) but the second-lowest healthcare expenditure levels (4.8% of total healthcare expenditure) among the studied major chronic diseases. Conclusions Our study suggests that the costs associated with treating cancer account for a low proportion of total healthcare expenditure relative to the burden of the disease and compared to other major chronic diseases across the countries included in the analysis.

scholarly journals Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018

2020 ◽  
Vol 38 (10) ◽  
pp. 1135-1145 ◽  
Author(s):  
David D. Kim ◽  
Madison C. Silver ◽  
Natalia Kunst ◽  
Joshua T. Cohen ◽  
Daniel A. Ollendorf ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Productivity Loss ◽  
Quality Adjusted Life Year ◽  
Healthcare Sector ◽  
Disability Adjusted Life ◽  
Payer Perspective ◽  
The Cost ◽  
Disability Adjusted Life Year ◽  
The Impact

Abstract Objective Our objective was to examine perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness ratios (ICERs). Methods We analyzed the Tufts Medical Center’s CEA and Global Health CEA registries, containing 6907 cost-per-quality-adjusted-life-year (QALY) and 698 cost-per-disability-adjusted-life-year (DALY) studies published through 2018. We examined how often published CEAs included non-health consequences and their impact on ICERs. We also reviewed 45 country-specific guidelines to examine recommended analytic perspectives. Results Study authors often mis-specified or did not clearly state the perspective used. After re-classification by registry reviewers, a healthcare sector or payer perspective was most prevalent (74%). CEAs rarely included unrelated medical costs and impacts on non-healthcare sectors. The most common non-health consequence included was productivity loss in the cost-per-QALY studies (12%) and patient transportation in the cost-per-DALY studies (21%). Of 19,946 cost-per-QALY ratios, the median ICER was $US26,000/QALY (interquartile range [IQR] 2900–110,000), and 18% were cost saving and QALY increasing. Of 5572 cost-per-DALY ratios, the median ICER was $US430/DALY (IQR 67–3400), and 8% were cost saving and DALY averting. Based on 16 cost-per-QALY studies (2017–2018) reporting 68 ICERs from both the healthcare sector and societal perspectives, the median ICER from a societal perspective ($US22,710/QALY [IQR 11,991–49,603]) was more favorable than from a healthcare sector perspective ($US30,402/QALY [IQR 10,486–77,179]). Most governmental guidelines (67%) recommended either a healthcare sector or a payer perspective. Conclusion Researchers should justify and be transparent about their choice of perspective and costing approaches. The use of the impact inventory and reporting of disaggregate outcomes can reduce inconsistencies and confusion.

Clostridium difficileinfection: epidemiology, disease burden and therapy

2013 ◽  
Vol 154 (30) ◽  
pp. 1188-1193 ◽  
Author(s):  
László Gulácsi ◽  
Adrienne Kertész ◽  
Irén Kopcsóné Németh ◽  
János Banai ◽  
Endre Ludwig ◽  
...  
Keyword(s):  
Public Health ◽  
Health Economics ◽  
Disease Burden ◽  
Hungarian Literature ◽  
Medline Database ◽  
The Cost ◽  
Vancomycin Treatment

Introduction:C. difficile causes 25 percent of the antibiotic associated infectious nosocomial diarrhoeas. C. difficile infection is a high-priority problem of public health in each country. The available literature of C. difficile infection’s epidemiology and disease burden is limited. Aim: Review of the epidemiology, including seasonality and the risk of recurrences, of the disease burden and of the therapy of C. difficile infection. Method: Review of the international and Hungarian literature in MEDLINE database using PubMed up to and including 20th of March, 2012. Results: The incidence of nosocomial C. difficile associated diarrhoea is 4.1/10 000 patient day. The seasonality of C. difficile infection is unproved. 20 percent of the patients have recurrence after metronidazole or vancomycin treatment, and each recurrence increases the chance of a further one. The cost of C. difficile infection is between 130 and 500 thousand HUF (430 € and 1665 €) in Hungary. Conclusions: The importance of C. difficile infection in public health and the associated disease burden are significant. The available data in Hungary are limited, further studies in epidemiology and health economics are required. Orv. Hetil., 2013, 154, 1188–1193.

Assessment of Gaming Practices and its effect on scholastic performance of medical students in India: A Case Control study. (Preprint)

2020 ◽  
Author(s):  
Deodatt Madhav Suryawanshi ◽  
Divya Rajaseharan 2nd ◽  
Raghuram Venugopal 3rd ◽  
Ramchandra Goyal 4th ◽  
Anju Joy 5th
Keyword(s):  
Medical Students ◽  
Case Control ◽  
Annual Growth Rate ◽  
Gaming Addiction ◽  
Gaming Disorder ◽  
Compound Annual Growth Rate ◽  
Internal Assessment ◽  
Assessment Scores ◽  
Scholastic Performance ◽  
Excessive Gaming

BACKGROUND Introduction: Gaming is a billion-dollar industry growing at a Compound annual growth rate (CAGR) of 9 %- 14.3% with biggest market in South East Asian countries. Availability of Low-cost smart phones, ease of internet access has made gaming popular among youth who enjoy it as a leisure activity. According to the WHO excessive indulgence in Gaming can lead to Gaming disorder. Medical students indulging in excessive gaming can succumb to gaming disorder which can affect their scholastic performance. Hence this study was done to assess the gaming practices and its effect on scholastic performance. OBJECTIVE Objective: 1. To assess the various Gaming practices and the Prevalence of Gaming addiction among medical students. 2. To study the effect of Gaming practices on Scholastic performance of medical students. METHODS Methods: The present study used a case control design where the 448(N) study participants were recruited using non probability sampling technique.91 (Nc) cases who were Gaming for past 6 months were identified using rapid preliminary survey .91 controls (Nco) who never played games were selected and matched for age and sex. Internal Assessment scores (%) of cases and controls were compared. Snedecor F test and Student t test were used to find out the association between the hours of gaming and internal assessment scores (%) and difference of Internal assessment scores between cases and controls respectively. Odds ratio was calculated to identify the risk of Poor scholastic performance. Prevalence of Gaming addiction was assessed using Lemmen’s Gaming addiction scale (GAS). RESULTS Results: Frequency of gaming (hrs) was not associated with the Mean internal assessment scores (p>0.05). Male students (cases) showed significant reduction in both their internal assessment scores (p<0.001,<0.01) whereas no reduction was observed in Female cases. A negative correlation was observed between GAS and internal assessment scores (r=-0.02). Prevalence of Gaming addiction using GAS was found to be 6.2% among the study population(N=448) and 31% among Cases (Nc=91).The risk of low scores was (OR =1.80-1.89) times more in cases than controls. CONCLUSIONS Conclusions: Excessive Gaming adversely affects scholastic performance in males than females.Awareness about Gaming addiction needs to be created among students, parents and teachers. Institutionalized De-addiction services should be made available to medical students. CLINICALTRIAL No

scholarly journals Burden of foodborne disease in the Netherlands: from science to policy

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
L Mughini Gras
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Cost Of Illness ◽  
Disease Burden ◽  
Food Groups ◽  
Source Attribution ◽  
Productivity Losses ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Animal Contact

Abstract In the Netherlands, the Ministry of Health mandates the National Institute for Public Health and the Environment (RIVM) to provide annual updates of the number of illnesses, disease burden and cost-of-illness caused by an agreed-upon standard panel of 14 enteric pathogens. These pathogens are mainly transmitted by food, but also via direct contact with animals, environment-mediated and human-to-human transmission routes. The disease burden is expressed in DALYs (Disability Adjusted Life Years), a metric integrating morbidity and mortality into one unit. Furthermore, the cost-of-illness (COI) related to these 14 pathogens is estimated and expressed in euros. The COI estimates include healthcare costs, the costs for the patient and/or his family, such as travel expenses, as well as costs in other sectors, for example due to productivity losses. Moreover, using different approaches to source attribution, the estimated DALYs and associated COI estimates are attributed to five major transmission pathways (i.e. food, environment, direct animal contact, human-human transmission, and travel) and 11 food groups within the foodborne pathway itself. The most recent DALY and COI estimates referring to the year 2018 show that the 14 pathogens in question are cumulatively responsible for about 11,000 DALYs and €426 million costs for the Dutch population in 2018, with a share for foodborne transmission being estimated at 4,300 DALYs and €171 million costs, which is comparable to previous years. These estimates have been providing vital insights for policy making as to guide public health interventions and resource allocation for over two decades in the Netherlands. Herewith, the approach and outcomes of the burden of disease and COI estimates in the Netherlands will be presented, with a focus on how these estimates enable policy-makers and the scientific community to monitor trends, generate scientific hypotheses, and undertake public health actions.

scholarly journals The impact of multimorbidity patterns on health-related quality of life in the general population: results of the Belgian Health Interview Survey

2021 ◽  
Author(s):  
Lisa Van Wilder ◽  
Brecht Devleesschauwer ◽  
Els Clays ◽  
Stefanie De Buyser ◽  
Johan Van der Heyden ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Diseases ◽  
Disease Burden ◽  
Health Related Quality ◽  
Health Interview Survey ◽  
Related Quality ◽  
Health Related ◽  
Interview Survey ◽  
The Impact

Abstract Background Chronic diseases and multimorbidity are a major cause of disease burden—for patients, caregivers, and society. Little is known however about potential interaction effects between specific disease combinations. Besides an additive effect, the presence of multiple conditions could also act synergistically or antagonistically regarding the impact on patients’ health-related quality of life (HRQoL). The aim was to estimate the impact of coexisting chronic diseases on HRQoL of the adult general Belgian population. Methods The Belgian Health Interview Survey 2018 provided data on self-reported chronic conditions and HRQoL (EQ-5D-5L) for a nationally representative sample. Linear mixed models were used to analyze two-way and three-way interactions of disease combinations on HRQoL. Results Multimorbidity had a prevalence of 46.7% (≥ 2 conditions) and 29.7% (≥ 3 conditions). HRQoL decreased considerably with the presence of multiple chronic diseases. 14 out of 41 dyad combinations and 5 out of 13 triad combinations showed significant interactions, with a dominant presence of negative/synergistic effects. Positive/antagonistic effects were found in more subjective chronic diseases such as depression and chronic fatigue. Conditions appearing the most frequently in significant disease pair interactions were dorsopathies, respiratory diseases, and arthropathies. Conclusions Diverse multimorbidity patterns, both dyads and triads, were synergistically or antagonistically associated with lower HRQoL. Tackling the burden of multimorbidity is needed, especially because most disease combinations affect each other synergistically, resulting in a greater reduction in HRQoL. Further knowledge about those multimorbidity patterns with a greater impact on HRQoL is needed to better understand disease burden beyond mortality and morbidity data.

Australian Biotechnology: A 10-Year Study of Investor Performance

2021 ◽  
Vol 26 (4) ◽  
Author(s):  
Peter L. Molloy ◽  
Lester W. Johnson ◽  
Michael Gilding
Keyword(s):  
Drug Development ◽  
Global Financial Crisis ◽  
Critical Mass ◽  
Share Price ◽  
Annual Growth Rate ◽  
Compound Annual Growth Rate ◽  
Listed Firms ◽  
Investor Returns ◽  
The Global Financial Crisis ◽  
The Impact

A recent study assessed the investor performance of the Australian drug development biotech (DDB) sector over a 15-year period from 2003 to 2018. The current study builds on that research and extends the analysis to 2020, using a 10-year period starting 2010, to exclude the impact of the global financial crisis in 2008/09. Based on a value-weighted portfolio of all 41 DDB firms, the overall sector delivered a negative annualized return of -4.1%. Individual firm performance was also assessed using the compound annual growth rate (CAGR) in share price over the period as a measure of investor outcomes. On this basis 68% of firms produced negative CAGRs over the period, and of the 32% of firms that produced positive CAGRs, six firms produced CAGRs greater than 20% per annum and in three cases of recently-listed firms, the CAGR’s were greater than 50%. Overall however, the sector overall delivered very poor investor returns and despite a relatively large number of listed biotech firms, Australian biotechnology continues to be small and weak in terms of its contribution to global biotechnology industrialization. As such it lacks the critical mass to grow a robust bioeconomy based on drug development, which remains the standard-bearer of biotechnology industrialization.

Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies

2021 ◽  
pp. 1-39
Author(s):  
Kevin Morris ◽  
Mohammad Nami ◽  
Joe F. Bolanos ◽  
Maria A. Lobo ◽  
Melody Sadri-Naini ◽  
...  
Keyword(s):  
Mental Disorders ◽  
Neurological Disorders ◽  
World Economy ◽  
Disease Burden ◽  
The United States ◽  
Fast Tracking ◽  
The World ◽  
Life Threatening ◽  
The Cost ◽  
The Impact

Neurological disorders significantly impact the world’s economy due to their often chronic and life-threatening nature afflicting individuals which, in turn, creates a global disease burden. The Group of Twenty (G20) member nations, which represent the largest economies globally, should come together to formulate a plan on how to overcome this burden. The Neuroscience-20 (N20) initiative of the Society for Brain Mapping and Therapeutics (SBMT) is at the vanguard of this global collaboration to comprehensively raise awareness about brain, spine, and mental disorders worldwide. This paper aims to provide a comprehensive review of the various brain initiatives worldwide and highlight the need for cooperation and recommend ways to bring down costs associated with the discovery and treatment of neurological disorders. Our systematic search revealed that the cost of neurological and psychiatric disorders to the world economy by 2030 is roughly $16T. The cost to the economy of the United States is $1.5T annually and growing given the impact of COVID-19. We also discovered there is a shortfall of effective collaboration between nations and a lack of resources in developing countries. Current statistical analyses on the cost of neurological disorders to the world economy strongly suggest that there is a great need for investment in neurotechnology and innovation or fast-tracking therapeutics and diagnostics to curb these costs. During the current COVID-19 pandemic, SBMT, through this paper, intends to showcase the importance of worldwide collaborations to reduce the population’s economic and health burden, specifically regarding neurological/brain, spine, and mental disorders.

Occupational class and chronic diseases in India

2017 ◽  
Author(s):  
Sanjay K. Mohanty ◽  
Anshul Kastor
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Diseases ◽  
Burden Of Illness ◽  
National Sample ◽  
Communicable Diseases ◽  
Sample Survey ◽  
Occupational Class ◽  
Respiratory Illnesses ◽  
Lifestyle Related Diseases ◽  
Nose And Throat

This chapter studies the differentials in chronic diseases among occupational classes in India. The results of the 60th round of National Sample Survey conducted from January to June 2004 show that those who are engaged as own-account workers in a household enterprise have the highest rate of reported disorders in joints and bones, respiratory illnesses including ear, nose, and throat ailments, and bronchial asthma during the last 15 days of the survey. Meanwhile, the leading diseases among employers are diabetes, cardiovascular disease, disorders of the joints and bones, hypertension, and gastritis. Furthermore, the higher reported prevalence of non-communicable diseases (NCDs) resulting from higher prevalence of lifestyle-related diseases among richer groups could have contributed to the greater burden of illness among them.

scholarly journals Cost-effectiveness of psychotherapy for cluster B personality disorders

2010 ◽  
Vol 196 (5) ◽  
pp. 396-403 ◽  
Author(s):  
Djøra I. Soeteman ◽  
Roel Verheul ◽  
Jos Delimon ◽  
Anke M. M. A. Meerman ◽  
Ellen van den Eijnden ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Personality Disorders ◽  
Cost Effective ◽  
Quality Adjusted Life Year ◽  
Decision Analytic Model ◽  
Day Hospital ◽  
Payer Perspective ◽  
Cluster B Personality Disorders ◽  
Effective Choice ◽  
The Cost

BackgroundRecommendations on current clinical guidelines are informed by limited economic evidence.AimsA formal economic evaluation of three modalities of psychotherapy for patients with cluster B personality disorders.MethodA probabilistic decision-analytic model to assess the cost-effectiveness of out-patient, day hospital and in-patient psychotherapy over 5 years in terms of cost per recovered patient-year and cost per quality-adjusted life-year (QALY). Analyses were conducted from both societal and payer perspectives.ResultsFrom the societal perspective, the most cost-effective choice switched from out-patient to day hospital psychotherapy at a threshold of €12 274 per recovered patient-year; and from day hospital to in-patient psychotherapy at €113 298. In terms of cost per QALY, the optimal strategy changed at €56 325 and €286 493 per QALY respectively. From the payer perspective, the switch points were at €9895 and €155 797 per recovered patient-year, and €43 427 and €561 188 per QALY.ConclusionsOut-patient psychotherapy and day hospital psychotherapy are the optimal treatments for patients with cluster B personality disorders in terms of cost per recovered patient-year and cost per QALY.

Sign in / Sign up

Export Citation Format

Share Document